Development of a human glioblastoma model using humanized DRAG mice for immunotherapy [0.03%]
人源化DRAG小鼠脑胶质瘤模型的建立及其免疫治疗效应研究
Rashmi Srivastava,Alireza Labani-Motlagh,Apeng Chen et al.
Rashmi Srivastava et al.
Glioblastoma (GBM) is the most common and lethal primary brain tumor. The development of alternative humanized mouse models with fully functional human immune cells will potentially accelerate the progress of GBM immunotherapy. We successfu...
Effects of arginine in therapeutic protein formulations: a decade review and perspectives [0.03%]
精氨酸在蛋白药物制剂中的作用：十年回顾及展望
Steven Ren
Steven Ren
Arginine (Arg) is a natural amino acid with an acceptable safety profile and a unique chemical structure. Arg and its salts are highly effective in enhancing protein refolding and solubilization, suppressing protein-protein interaction and ...
In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2 [0.03%]
体外生成的抗体引导设计稳定的ADDomer纳米颗粒以用于新型冠状病毒鼻腔疫苗及被动免疫疗法
Dora Buzas,Adrian H Bunzel,Oskar Staufer et al.
Dora Buzas et al.
Background: Due to COVID-19, pandemic preparedness emerges as a key imperative, necessitating new approaches to accelerate development of reagents against infectious pathogens. ...
Bringing cell therapy to tumors: considerations for optimal CAR binder design [0.03%]
使细胞疗法作用于肿瘤：关于最佳CAR结合器设计的考量因素
Richard Smith
Richard Smith
Chimeric antigen receptor (CAR)-T cells have revolutionized the immunotherapy of B-cell malignancies and are poised to expand the range of their impact across a broad range of oncology and non-oncology indications. Critical to the success o...
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy [0.03%]
人源化单克隆抗体IMM47通过靶向CD24抑制CD24与Siglec-10相互作用可单独使用或与抗PD1抗体联合用于癌症免疫治疗并表现出优异的抗肿瘤效果
Song Li,Dianze Chen,Huiqin Guo et al.
Song Li et al.
This study evaluates the anti-tumor mechanism of IMM47, a humanized anti-CD24 mAb. Biolayer interferometry, ELISA and flow cytometry methods were used to measure the IMM47 binding, affinity, ADCC, ADCP, ADCT and CDC activities. In vivo ther...
Comparability strategy and demonstration for post-approval production cell line change of a bevacizumab biosimilar IBI305 [0.03%]
贝伐珠单抗类似药IBI305上市后生产细胞系变更的可比性研究及验证
Zhouyi Wu,Gangling Xu,Wu He et al.
Zhouyi Wu et al.
High-producing cell line could improve the affordability and availability of biotherapeutic products. A post-approval production cell line change, low-titer CHO-K1S to high-titer CHO-K1SV GS-KO, was performed for a China marketed bevacizuma...
The influence of variable-heavy chain families on IgG2, 3, 4, FcγRs and B-cell superantigens protein G and L binding using biolayer interferometry [0.03%]
采用生物层干涉测量技术研究可变重链基因型对IgG亚类、FcγRs和B细胞超抗原蛋白G和L的结合的影响
Anthony M Deacy,Samuel Ken-En Gan
Anthony M Deacy
As the most abundant immunoglobulin in blood and the most common human isotype used for therapeutic monoclonal antibodies, the engagement and activation of its Fc receptors by IgGs are crucial for antibody function. Assumed to be relatively...
Alpaca single B cell interrogation and heavy-chain-only antibody discovery on an optofluidic platform [0.03%]
基于光流片上细胞操控平台的羊驼单B淋巴细胞筛选与仅重链抗体发现技术
Mariya B Shapiro,Jacqueline Boucher,Anna Brousseau et al.
Mariya B Shapiro et al.
In vivo VHH discovery approaches have been limited by the lack of methodologies for camelid B cell interrogation. Here, we report a novel application of the Beacon® optofluidic platform to the discovery of heavy-chain-only antibodies by sc...
Correction: AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains [0.03%]
纠误：AB-Amy：借助机器学习预测治疗性单克隆抗体轻链淀粉样变风险
[This corrects the article DOI: 10.1093/abt/tbad007.]. © The Author(s) 2023. Published by Oxford University Press on behalf of Antibody Therapeutics. Al...
Published Erratum
Antibody therapeutics. 2023 May 26;6(3):180. DOI:10.1093/abt/tbad012 2023
Correction to: A mammalian cell display platform based on scFab transposition [0.03%]
Correction to: 培植基于scFab转座的哺乳动物细胞展示平台
[This corrects the article DOI: 10.1093/abt/tbad009.]. © The Author(s) 2023. Published by Oxford University Press on behalf of Antibody Therapeutics. Al...
Published Erratum
Antibody therapeutics. 2023 Jul 7;6(3):181. DOI:10.1093/abt/tbad015 2023